FDA trial shows sustained effect for Ozurdex on diabetic
The dexamethasone intraocular implant OZURDEX® (Allergan)
can bring about significant and visual improvement in patients
with diabetic macular oedema, with generally only transient
increases in IOP but with a high incidence of cataract in
phakic patients, said EURETINA president ,Francesco
Bandello MD, told attendees at an EURETINA free paper
session
He reported the pooled results of two FDA studies conducted
by the MEAD study group involving a total of 1048 patients
with diabetic macular oedema. The patients were randomised
into three groups to receive Ozurdex at a dosage of 0.7 mg or
0.35 mg , or sham treatment, with repeated injections when
indicated at intervals no shorter than six months.
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.